Industry / South Africa
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Adcock Ingram On Collision Course With Regulator Over Direct-To-Consumer Advertising
October 2007 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
South Africa's Adcock Ingram has found itself on the wrong side of the Medicines Control Council (MCC) after the regulator alleged Adcock has persistently engaged in illegal direct-to-consumer advertising of a flagship prescription drug. By law, drugs classified as 'schedule two' and higher may be advertised only to authorised prescribers - namely doctors and pharmacists. The drug in question - analgesic Myprodol (ibuprofen + paracetamol + codeine) - is a 'schedule three' drug and, according to the regulator, has been illegally advertised through magazines and television 'on numerous occasions' directly to